© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
Latest Conference Articles
Gene therapy offers first steps in treatment of achromatopsia
May 14th 2021
Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.
Foveal morphologic changes in LCA sparked by gene therapy
May 10th 2021
In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.
Analysis of 24-month data from the PALADIN study
May 7th 2021
Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
A look at real-world trial data replication outcomes from IRIS Registry data
May 6th 2021
Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.
Linking patient imaging data to AAO IRIS Registry
May 6th 2021
Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.
Analyzing clinical results of dexamethasone implant effect on macular thickness
May 5th 2021
Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Diabetes and DR: Progress in a global epidemic
May 5th 2021
Clinicians' knowledge of the epidemiology, natural history, causal mechanisms, and treatments for diabetic retinopathy (DR) has evolved dramatically over recent decades.
Wet AMD treatment burden eased by nonviral gene therapy
May 3rd 2021
EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.
Novel factors predict ocriplasmin efficacy in symptomatic vitreomacular traction
May 3rd 2021
Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.
Targeting neurodegenerative diseases with risuteganib as treatment therapy
May 3rd 2021
Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.